Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Sarcoma 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Ganglioneuroblastoma 2Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neuroblastoma 1Myeloproliferative Disorders 1Localized Extraskeletal Ewing Sarcoma 1Leukemia, Biphenotypic, Acute 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

venetoclax 188Azacitidine 160Cytarabine 127fludarabine 96Cyclophosphamide 74Specimen Handling 68fludarabine phosphate 56Daunorubicin 53Biopsy 49Decitabine 47Whole-Body Irradiation 42Mycophenolic Acid 40Idarubicin 40Busulfan 37Tacrolimus 35Injections 35Granulocyte Colony-Stimulating Factor 35Melphalan 32Stem Cell Transplantation 30gilteritinib 25Filgrastim 25CPX-351 25decitabine and cedazuridine drug combination 23Peripheral Blood Stem Cell Transplantation 22Etoposide 20Mitoxantrone 19Cladribine 19ivosidenib 18Thiotepa 17Sirolimus 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × Razoxane × 1 year × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Children's Oncology Group

Phase 3 Recruiting
1,186 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡